Literature DB >> 17161039

Single-photon emission computed tomography/computed tomography in abdominal diseases.

Orazio Schillaci1, Luca Filippi, Roberta Danieli, Giovanni Simonetti.   

Abstract

Single-photon emission computed tomography (SPECT) studies of the abdominal region are established in conventional nuclear medicine because of their easy and large availability, even in the most peripheral hospitals. It is well known that SPECT imaging demonstrates function, rather than anatomy. It is useful in the diagnosis of various disorders because of its ability to detect changes caused by disease before identifiable anatomic correlates and clinical manifestations exist. However, SPECT data frequently need anatomic landmarks to precisely depict the site of a focus of abnormal tracer uptake and the structures containing normal activity; the fusion with morphological studies can furnish an anatomical map to scintigraphic findings. In the past, software-based fusion of independently performed SPECT and CT or magnetic resonance images have been demonstrated to be time consuming and not useful for routine clinical employment. The recent development of dual-modality integrated imaging systems, which provide SPECT and CT images in the same scanning session, with the acquired images co-registered by means of the hardware, has created a new scenario. The first data have been mainly reported in oncology patients and indicate that SPECT/CT is very useful because it is able to provide further information of clinical value in several cases. In SPECT studies of abdominal diseases, hybrid SPECT/CT can play a role in the differential diagnosis of hepatic hemangiomas located near vascular structures, in precisely detecting and localizing active splenic tissue caused by splenosis in splenectomy patients, in providing important information for therapy optimization in patients submitted to hepatic arterial perfusion scintigraphy, in accurately identifying the involved bowel segments in patients with inflammatory bowel diseases, and in correctly localizing the bleeding sites in patients with gastrointestinal bleeding.

Entities:  

Mesh:

Year:  2007        PMID: 17161039     DOI: 10.1053/j.semnuclmed.2006.07.001

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  6 in total

1.  Is PET always an advantage versus planar and SPECT imaging?

Authors:  Giuliano Mariani; Laura Bruselli; Adriano Duatti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

2.  SPECT/CT imaging in ⁹⁹mTc-HSA-DTPA gastrointestinal bleeding scintigraphy to localize bleeding sites.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-05       Impact factor: 9.236

Review 3.  Acquisition parameters for oncologic imaging with a new SPECT/multislice CT scanner.

Authors:  Rodolfo Núñez; William D Erwin; Richard E Wendt; Anne Stachowiak; Martha Mar; Donna Stevens; John E Madewell; Henry W Yeung; Homer A Macapinlac
Journal:  Mol Imaging Biol       Date:  2010-01-05       Impact factor: 3.488

4.  Selective Spleen Scintigraphy in the Evaluation of Accessory Spleen/Splenosis in Splenectomized/Nonsplenectomized Patients and the Contribution of SPECT Imaging.

Authors:  Şeyma Ekmekçi; Reyhan Diz-Küçükkaya; Cüneyt Türkmen; Işık Adalet
Journal:  Mol Imaging Radionucl Ther       Date:  2015-02-05

5.  Diffuse abdominal splenosis mimicking peritoneal metastases in a 35-year-old man with a resectable carcinoma of the ampulla of vater.

Authors:  Steffen Filskov Sorensen; Frank Viborg Mortensen; Ylva Hellberg; Morten Ladekarl
Journal:  Case Rep Oncol       Date:  2013-09-14

6.  A Lower Gastrointestinal Bleeding Due to a Post-Traumatic Splenosis: "Wait and See" Represents a Feasible Attitude: A Case Report.

Authors:  Fausto Famà; Giuseppa Giacobbe; Marcello Cintolo; Maria Gioffré-Florio; Socrate Pallio; Pierluigi Consolo
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.